Clinical trials: Elderly Lymphoma Patients
Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in Korea. Although there is standard therapy, which is called 'R-CHOP', many obstacles to use aggressive cytotoxic chemotherapeutic agents such…
- Trial name
- NCT01676558
- Testing
- 131I-rituximab
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Korea Cancer Center Hospital
Double Expressor DLBCL
Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL
This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with…
- Trial name
- NCT07415980
- Testing
- Polatuzumab Vedotin, Rituximab (R), Chidamide
- Volunteers
- 68 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278421
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in Germany, Israel and 1 more
- Volunteers
- 592 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Primary Central Nervous System Lymphoma
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually…
- Trial name
- FIORELLA (NCT03495960)
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 34 sites in Denmark, Finland and 2 more
- Volunteers
- 72 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large Cell Lymphoma
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
This study is a multicentric randomized trial evaluating the efficacy and safety of R-CHOP given every 14 days compared to R-CHOP given every 21 days in association or not with darbepoetin alfa in order to maintain hemoglobin…
- Trial name
- NCT00144755
- Testing
- Darbepoetin alfa
- Where
- 14 sites in Belgium, France and 1 more
- Volunteers
- 600 people
- Sponsor
- Lymphoma Study Association
Classical Hodgkin Lymphoma
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
This study evaluates bendamustine in patients aged over 60 years with classical Hodgkin Lymphoma treated by prednisone, vinblastine and doxorubicin. 90 patients will be enrolled in this study.
- Trial name
- PVAB (NCT02414568)
- Testing
- Bendamustine, Prednisone, Vinblastine
- Where
- 40 sites in Belgium, France
- Volunteers
- 90 people
- Sponsor
- The Lymphoma Academic Research Organisation
Lymphoma
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell transplant helps stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392691
- Testing
- ibritumomab tiuxetan, rituximab, melphalan
- Where
- 10 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Swiss Cancer Institute
Adult Solid Neoplasm, Toxicity
Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body.
- Conditions
- Adult Solid Neoplasm, Toxicity, Lymphoma
- Trial name
- NCT02054741
- Testing
- Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Survey Administration
- Where
- 23 sites in United States
- Volunteers
- 733 people
- Sponsor
- Supriya Mohile
Hodgkin's Disease
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.
- Trial name
- NCT00147875
- Testing
- Prednisone, Vinblastine, Doxorubicin (Adriamycin)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Cologne
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL.
- Trial name
- NCT01203930
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Aged, Aged, 80 and Over
An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies
Older people with cancer differ from younger patients due to the combined effects of aging, comorbidities and cancer treatments on their health.
- Conditions
- Aged, Aged, 80 and Over, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin
- Trial name
- OCAPI (NCT04052126)
- Testing
- Individualized physical activity program
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Centre Leon Berard
Lymphoma, Mantle-Cell
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
The aim of this study is to answer the following independent questions in the treatment of mantle cell lymphomas: Can rituximab-fludarabine, cyclophosphamide (R-FC) improve the reduction of lymphoma mass compared to…
- Trial name
- MCLelderly (NCT00209209)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 7 sites in Czechia, Denmark and 5 more
- Volunteers
- 570 people
- Sponsor
- European Mantle Cell Lymphoma Network
Diffuse Large B Cell Lymphoma
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05809180
- Testing
- Rituximab, Orelabrutinib, Pomalidomide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia
EWALL-PH OBSERVARTORY 2022
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or…
- Trial name
- Ewall Obs 2022 (NCT07684131)
- Where
- 23 sites in France
- Volunteers
- 100 people
- Sponsor
- Versailles Hospital
Non-Hodgkin's Lymphoma
Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
This is an exploratory analysis that is investigating the pattern of care in patients over the age of 80 who were diagnosed with non-Hodgkin lymphoma (NHL).
- Trial name
- NCT00902434
- Volunteers
- 50 people
- Sponsor
- Oncology Specialists, S.C.
Lymphoma
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or…
- Trial name
- NCT00079105
- Testing
- bleomycin sulfate, cyclophosphamide, etoposide
- Where
- 54 sites in Germany, United Kingdom
- Volunteers
- 175 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Lymphoma, Large B-Cell, Diffuse
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP regimen) has been the first-line chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02428751
- Testing
- Pegylated liposomal doxorubicin, Doxorubicin, Rituximab
- Where
- 7 sites in China
- Volunteers
- 216 people
- Sponsor
- Wenqi Jiang
Diffuse Large B-cell Lymphoma
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
- Trial name
- NCT00968331
- Testing
- Lenalidomide plus Rituximab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Bologna
T-cell Lymphoma
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
This study aims to evaluate the efficacy of lenalidomide associated with CHOP as measured by complete response rate at the end of treatment.
- Trial name
- NCT01553786
- Testing
- Lenalidomide
- Where
- 30 sites in Belgium, France
- Volunteers
- 80 people
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B-Cell Lymphoma
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the…
- Trial name
- NCT06764017
- Testing
- CHiR-DEL
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Ningbo University